CN102186820B - Rassf1a表达和人癌细胞增殖的荧光调节剂 - Google Patents

Rassf1a表达和人癌细胞增殖的荧光调节剂 Download PDF

Info

Publication number
CN102186820B
CN102186820B CN2009801406819A CN200980140681A CN102186820B CN 102186820 B CN102186820 B CN 102186820B CN 2009801406819 A CN2009801406819 A CN 2009801406819A CN 200980140681 A CN200980140681 A CN 200980140681A CN 102186820 B CN102186820 B CN 102186820B
Authority
CN
China
Prior art keywords
rassf1a
cancer
cells
cell
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801406819A
Other languages
English (en)
Chinese (zh)
Other versions
CN102186820A (zh
Inventor
密尔顿·L·布朗
凯瑟琳·D·谢赫
米凯尔·佩奇
帕索·班纳吉
尚卡尔·加格德施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of CN102186820A publication Critical patent/CN102186820A/zh
Application granted granted Critical
Publication of CN102186820B publication Critical patent/CN102186820B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2009801406819A 2008-08-15 2009-08-14 Rassf1a表达和人癌细胞增殖的荧光调节剂 Expired - Fee Related CN102186820B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18905908P 2008-08-15 2008-08-15
US61/189,059 2008-08-15
PCT/US2009/004681 WO2010019271A1 (en) 2008-08-15 2009-08-14 Fluorescent regulators of rassf1a expression and human cancer cell proliferation

Publications (2)

Publication Number Publication Date
CN102186820A CN102186820A (zh) 2011-09-14
CN102186820B true CN102186820B (zh) 2013-08-28

Family

ID=41279343

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801406819A Expired - Fee Related CN102186820B (zh) 2008-08-15 2009-08-14 Rassf1a表达和人癌细胞增殖的荧光调节剂

Country Status (9)

Country Link
US (1) US10457639B2 (https=)
EP (2) EP2323982B1 (https=)
JP (2) JP2012500197A (https=)
CN (1) CN102186820B (https=)
AT (1) ATE547403T1 (https=)
AU (1) AU2009282451B2 (https=)
BR (1) BRPI0917411A2 (https=)
CA (1) CA2734225A1 (https=)
WO (1) WO2010019271A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
ES2641642T3 (es) 2010-03-08 2017-11-10 Monsanto Technology Llc Moléculas de polinucleótido para regulación génica en plantas
US8637679B2 (en) 2011-03-11 2014-01-28 Council Of Scientific And Industrial Research Process for the isolation of organic compounds useful for the treatment of cancer
EP3382027A3 (en) 2011-09-13 2018-10-31 Monsanto Technology LLC Methods and compositions for weed control
WO2013040057A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
CA2848695A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and composition for weed control comprising inhibiting ppg oxidase
MX348495B (es) 2011-09-13 2017-06-14 Monsanto Technology Llc Metodos y composiciones para el control de malezas.
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
MX361938B (es) 2011-09-13 2018-12-19 Monsanto Technology Llc Métodos y composiciones para el control de malezas.
MX360866B (es) 2012-05-24 2018-11-09 A B Seeds Ltd Composiciones y métodos para silenciar la expresión genética.
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
UY35252A (es) 2013-01-01 2014-07-31 Seeds Ltd Ab MÉTODOS PARA INTRODUCIR dsRNA EN SEMILLAS DE PLANTAS PARA MODULAR LA EXPRESIÓN GENÉTICA
BR112015023051A2 (pt) 2013-03-13 2017-11-14 Monsanto Technology Llc método para controle de ervas daninhas, composição herbicida, cassete de expressão microbiano e método de produção de polinucleotídeo
US10612019B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
WO2014151317A1 (en) * 2013-03-15 2014-09-25 Rush University Medical Center Methods for treating cancer
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
EP3030663B1 (en) 2013-07-19 2019-09-04 Monsanto Technology LLC Compositions and methods for controlling leptinotarsa
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
AU2014341879B2 (en) 2013-11-04 2020-07-23 Greenlight Biosciences, Inc. Compositions and methods for controlling arthropod parasite and pest infestations
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
WO2015108982A2 (en) 2014-01-15 2015-07-23 Monsanto Technology Llc Methods and compositions for weed control using epsps polynucleotides
WO2015153339A2 (en) 2014-04-01 2015-10-08 Monsanto Technology Llc Compositions and methods for controlling insect pests
CN106795515B (zh) 2014-06-23 2021-06-08 孟山都技术公司 用于经由rna干扰调控基因表达的组合物和方法
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
CN106604993A (zh) 2014-07-29 2017-04-26 孟山都技术公司 用于控制昆虫害虫的组合物和方法
CN108064288B (zh) 2015-01-22 2021-11-26 孟山都技术公司 用于控制叶甲属的组合物和方法
EP3302053B1 (en) 2015-06-02 2021-03-17 Monsanto Technology LLC Compositions and methods for delivery of a polynucleotide into a plant
WO2016196782A1 (en) 2015-06-03 2016-12-08 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
WO2017023916A1 (en) 2015-08-05 2017-02-09 Georgetown University Small molecule androgen receptor inhibitors and methods of use thereof
JP7236382B2 (ja) * 2017-06-12 2023-03-09 昇平 宮田 抗癌剤及びその使用
CN107266356B (zh) * 2017-07-25 2020-06-26 山西省生物研究院有限公司 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051523A2 (en) * 2006-10-23 2008-05-02 Georgetown University Carbazole derivatives useful as medicaments in cancer therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2235815A1 (de) * 1972-07-21 1974-01-31 Bayer Ag Polyazofarbstoffe
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
GB9215361D0 (en) 1992-07-20 1992-09-02 Wellcome Found Heterocyclic compounds
US5834462A (en) * 1993-07-26 1998-11-10 Eisai Co., Ltd. Tricyclic heterocyclic sulfonamide and sulfonic ester derivatives
JP3690825B2 (ja) * 1993-07-26 2005-08-31 エーザイ株式会社 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体
CA2186412A1 (en) * 1995-10-31 1997-05-01 Katherine S. Takaki Ethylamino carbazole melatonergic agents
JP3887769B2 (ja) 1997-12-22 2007-02-28 バイエル コーポレイション 対称および非対称ジフェニル尿素を用いるｐ３８キナーゼの阻害
WO2000063171A1 (en) * 1999-04-20 2000-10-26 Meiji Seika Kaisha, Ltd. Tricyclic compounds
KR20020069215A (ko) 1999-12-16 2002-08-29 아사히 가세이 가부시키가이샤 신규한 치환기를 갖는 3환성 화합물
AU2001252575A1 (en) 2000-04-28 2001-11-12 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
KR20090090406A (ko) * 2000-12-18 2009-08-25 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 염증성 사이토카인 생산 유리 억제제
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
JPWO2002074306A1 (ja) 2001-03-19 2004-07-08 旭化成ファーマ株式会社 脂肪肝治療薬
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US20100063126A1 (en) 2004-06-29 2010-03-11 Jadolabs Gmbh Carbazole-Derived Pharmaceutical Compositions
WO2006018405A1 (en) 2004-08-18 2006-02-23 Ciba Specialty Chemicals Holding Inc. Oxime ester photoinitiators
ITMI20051523A1 (it) 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
DE112006002340T5 (de) 2005-09-01 2008-07-17 Council Of Scientific And Industrial Research Arzneimittel, verwendbar zur Behandlung von Prostatakrebs
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
NZ567266A (en) 2005-10-13 2010-09-30 Orchid Res Lab Ltd Carbazole derivatives as pSTAT3/IL-6 inhibitors (carvedilol)
IL186935A0 (en) * 2006-10-31 2008-02-09 Veridex Llc Prostate cancer field effect analysis methods and kits
AU2008345036A1 (en) * 2007-12-28 2009-07-09 John Wayne Cancer Institute Use of methylation status of MINT loci and tumor-related genes as a marker for melanoma and breast cancer
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051523A2 (en) * 2006-10-23 2008-05-02 Georgetown University Carbazole derivatives useful as medicaments in cancer therapy

Also Published As

Publication number Publication date
WO2010019271A1 (en) 2010-02-18
BRPI0917411A2 (pt) 2015-12-01
EP2323982B1 (en) 2012-02-29
JP2012500197A (ja) 2012-01-05
ATE547403T1 (de) 2012-03-15
CN102186820A (zh) 2011-09-14
JP2014148545A (ja) 2014-08-21
EP2484666A1 (en) 2012-08-08
HK1158206A1 (en) 2012-07-13
AU2009282451A1 (en) 2010-02-18
CA2734225A1 (en) 2010-02-18
US20110152339A1 (en) 2011-06-23
EP2323982A1 (en) 2011-05-25
US10457639B2 (en) 2019-10-29
WO2010019271A8 (en) 2011-03-31
AU2009282451B2 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
CN102186820B (zh) Rassf1a表达和人癌细胞增殖的荧光调节剂
JP4989976B2 (ja) 翻訳開始阻害剤としての３−３−二置換オキシインドール
EP2673250B1 (en) Stilbene analogs and methods of treating cancer
CA2953079C (en) Intermittent dosing of mdm2 inhibitor
JP2020513789A (ja) ヘテロ二官能性化合物を用いた調整可能な内因性タンパク質分解
JP2014012706A (ja) 抗がん活性を有する化合物
US20100130579A1 (en) Cancer therapy
FR2921927A1 (fr) Imidazo[1,2-a]quinoxalines et derives pour le traitement des cancers
JP2014531402A5 (https=)
JP2014531402A (ja) 新規アニリン誘導体及びこれの用途（Ｎｏｖｅｌａｎｉｌｉｎｅｄｅｒｉｖａｔｉｖｅｓａｎｄｕｓｅｔｈｅｒｅｏｆ）
AU2015314772A1 (en) Compositions and methods for treatment of prostate carcinoma
JP2013518906A (ja) 複製タンパク質ａを阻害する物質および方法ならびにその使用
WO2009107322A1 (ja) がん治療用医薬組成物
AU2015225828B2 (en) Mcl-1 modulating compounds for cancer treatment
US10450295B2 (en) Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
AU2014202507B2 (en) Fluorescent regulators of RASSF1A expression and human cancer cell proliferation
US9175001B2 (en) [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
HK1158206B (en) Fluorescent regulators of rassf1a expression and human cancer cell proliferation
WO2013121385A1 (fr) Utilisation de dérivés de carbazolophénone pour le traitement du cancer
JP2025523463A (ja) Ｍｙｃ調節を含む組み合わせ療法
WO2018076537A1 (zh) D-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
TWI415611B (zh) 喹啉衍生物及其應用
SK500742020A3 (sk) Zlúčenina cemtirestat disulfid, prekurzor inhibítora aldoketoreduktáz, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie
WO2013037800A1 (fr) Utilisation de la 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methyl-propyl]amino-3,4-dihydro-2h-1,5-benzoxathiepine pour le traitement du cancer et en particulier pour la prevention et/ou le traitement des metastases cancereuses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130828

Termination date: 20180814